There is no right career path: A perspective from an immigrant physician-scientist and neuropathologist

Subhojit Roy, MD, PhD recently wrote an interesting post on his journey as a immigrant physician-scientist in the United States. Here's the link. His conclusion:

"Some amount of foresight and planning is obviously important for success in any field. But most successful careers do not follow a prescribed trajectory. It’s debatable whether meticulous career forecasting and vetting is any better than planning for the future in broad strokes, leaving some things to chance, and believing that one always has the power to make a change. Life is an exploration, not a Cuneiform tablet. And there is no such thing as the right career path."

Brain Pathology and the International Society of Neuropathology have established Twitter accounts

For readers wanting updates on the latest developments in neuropathology via social media, I recommend two Twitter accounts:

Brian Pathology

International Society of Neuropathology (ISN)

Among recent tweets were a link to a minisymposium on the molecular pathogenesis of prion diseases (Brain Pathology) and the latest news about the upcoming AANP meeting (ISN).

J. Hume Adams has passed away

J. Hume Adams in 1972

J. Hume Adams, Professor of Neuropathology in Glasgow, has died. With David Graham, Adams edited the fourth and fifth editions of Greenfield's Neuropathology. During his career, Adams made great advances in the study of neurotrauma.

Neuropathologist Matija Snuderl featured in major journal discussing the use of artificial intelligence in cancer diagnostics

Matija Snuderl, MD

Dr. Matija Snuderl, neuropathologist and molecular pathologist at  New York University Langone Health, was featured in a recent article appearing in Nature (March 26, 2020, Vol 579, p S14-S16). The article, which addresses the use of artificial intelligence (AI) in cancer diagnostics, opens with Dr. Snuderl experiencing a moment that many of us neuropathologists have had wherein we hesitate before signing out a case because of a feeling that something might be just a bit different about a particular specimen. That feeling prompts us to do something else (run more ancillary testing, get a consult, sleep on it and take another look the next day, etc.). In Dr. Snuderl's case, he was looking at a case which was thought to be a recurrence of a medulloblastoma in a young girl. Some of the histologic features didn't quite fit with medulloblastoma. "So, to help him make up his mind, Snuderl turned to a computer. He arranged for the girl to have a full-genome methylation analysis," writes Neil Savage, author of the article. Snuderl relays the result of this investigation: "The tumor came back as a glioblastoma...  If I had finalized the case just on pathology, I would have been terribly wrong." The AI system Snuderl used involved a database of thousands of tumor methylation profiles at the German Cancer Research Center. NYU Langone's Perlmutter Cancer Center is applying AI to the classification of tumors of all sorts, not only using pathologic samples, but also MR imaging, mammograms, and other means of diagnosis.

Thanks to Dr Snuderl for representing the important role neuropathologists play in cancer diagnostics in the age of molecular medicine and article intelligence. Thanks also to Dr. Michael Lawlor, of the Medical College of Wisconsin, for alerting me to this article!

Lost Smell and Taste Hint COVID-19 Can Target the Nervous System

Matthew Anderson, MD, PhD

Dr. Matt Anderson, chief of neuropathology at Beth Israel in Boston, forwarded me a recent article from The Scientist. The article describes the experience of Alessandro Laurenzi, a biologist working in Bologna, Italy, regarding the proposition that COVID-19 infected patients can have transient loss of the sense of smell. Olfactory sensory loss may play a role in early diagnosis, but it may also help in understanding pathogensis.

Dr. Anderson is quoted in the article, stating that central nervous system involvement by the virus may play a part in the respiratory symptomatology.

George Perry, former AANP president, granted meritorious award by the American Society for Investigative Pathology

George Perry, PhD

It was recently announced that Dr. George Perry has been given the Rous-Whipple Award by the American Society for Investigative Pathology.  According to the ASIP website, the Rous-Whipple Award "is presented to a senior scientist with a distinguished career in research who has advanced the understanding of disease and has continued productivity at the time of the award."

Congratulations, Dr. Perry. And thanks to Dr. Charles White for sharing this news.

David Solomon and Gregory Fuller garner prestigious awards at USCAP annual meeting

David Solomon, MD, PhD

Dr. David A. Solomon, assistant professor at UCSF, has been awarded the Ramzi S. Cotran Young Investigator Award at the recent annual meeting of the United States & Canadian Academy of Pathology (USCAP) for his work on diciphering the molecular pathogenesis of various brain neoplasms.

Also at this year's USCAP meeting, Gregory N. Fuller, MD, PhD was awarded the Harvey Goldman Teaching Award. Among his many contributions to pathology education is authoring the CNS chapter of the latest edition of the textbook Histology for Pathologists (2019).

Best Post of October 2019: Cytoplasmic Bodies in a Muscle Biopsy

The next in our "Best of the Month" series comes from October 7, 2019:

The inimitable Dr. Christian Davidson, formerly of Robert Wood Johnson Medical School at Rutgers and now at the University of Utah, sent in pictures of cytoplasmic bodies in a muscle biopsy from a patient with severe myositis. Thank you, Dr. Davidson!

Trichrome

Electron Microscopy

Werner Paulus launches freeneuropathology.org

Prof. Dr. Werner Paulus

Dr. Werner Paulus of the University of Munster, Germany, recently wrote in to share news of an exciting venture he and his colleagues have just launched:

"After editing Acta Neuropathologica for 14 years and after founding and editing Acta Neuropathologica Communications for 5 years, I have stepped down by the end of 2018 as editor of these two journals. A few weeks ago, together with colleagues from around the world, I have launched freeneuropathology.org . This is not just another neuropath journal, it´s a new type of publishing model without publisher. The “trick” is that scientists undertake the classical job of the publisher such as copyediting, layout, promotion, maintenance of the website etc. This makes the journal more efficient and more flexible, and it makes more fun because we can design the journal as we like and do not have to follow the business-driven interests of commercial publishers. It´s entirely free for readers and for authors (diamond open access). It´s from neuropathologists for neuropathologists, based on enthusiasm and voluntariness. We are very excited about this new approach and think that this might be the future of publishing in general, not only in the field of neuropathology. If you are interested, you can find more background information on the journal website and in the inaugural editorial: https://www.uni-muenster.de/Ejournals/index.php/fnp/article/view/2610/2480"